Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and female subjects must be 18 - 49 years of age at screening visit.
Subjects must have a body mass index < 35 kg/m2 at screening visit.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes after each vaccine administration
Awards & highlights
Study Summary
This study is evaluating whether there is consistency in the immunogenicity of three lots of Coronavirus-like Particle (CoVLP).
Eligible Conditions
- COVID-19
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ seven days following each vaccination
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~seven days following each vaccination
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
GMTs of the three vaccine lots
Secondary outcome measures
GMFRs
Immediate adverse events
Other adverse events
+3 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: Group 3Experimental Treatment1 Intervention
CoVLP Lot 3
Group II: Group 2Experimental Treatment1 Intervention
CoVLP Lot 2
Group III: Group 1Experimental Treatment1 Intervention
CoVLP Lot 1
Find a Location
Who is running the clinical trial?
MedicagoLead Sponsor
18 Previous Clinical Trials
59,360 Total Patients Enrolled
3 Trials studying COVID-19
31,226 Patients Enrolled for COVID-19
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger